Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of BCG-PPD in Healthy People
NCT04593771Phase 1Completed
- Sponsor
- Zhifei Biological
- Start
- Oct 2020
- Primary completion
- May 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bacillus calmette-guérin purified protein derivative in Tuberculosis (TB) (2 arms), sponsored by Zhifei Biological. Primary endpoints: Incidence of all adverse events and laboratory test abnormalities at 7 days and Size of skin response (induration and redness) at 72 hours. Started Oct 2020; status: completed.
02
Drugs
bacillus calmette-guérin purified protein derivative
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT04593771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04593771.